Regenerex Pharma Quick Ratio (RGPX) starting from the second quarter 2025 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
REGENEREX PHARMA, INC.  (OTC: RGPX)

Regenerex Pharma's Quick Ratio

RGPX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2025, Quick Ratio deteriorated to 0 a new company low.

Within Major Pharmaceutical Preparations industry REGENEREX PHARMA, INC. booked the highest Quick Ratio than Regenerex Pharma in the second quarter 2025. While Quick Ratio total ranking in the second quarter 2025 has deteriorated compared to the prior quarter from 4967 to 5340.

Explain Quick Ratio?
How much Cash & cash equivalents RGPX´s has?
What are RGPX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RGPX Quick Ratio (Sep 30 2025)
Q2		 (Jun 30 2025)
Q1		 (Mar 31 2025)
Q4		 (Dec 31 2024)
Q3		 (Sep 30 2024)
Q2
Y / Y Current Liabilities Change 5.17 % 15.62 % 27.6 % 31.7 % 31.22 %
Y / Y Cash & cash equivalent Change 3800 % - 163150 % -96.2 % -95.08 %
Quick Ratio MRQ 0 0.04 0.17 0 0
RGPX's Total Ranking # 5340 # 4967 # 4237 # 6006 # 5630
Seq. Current Liabilities Change -0.07 % 0.33 % 1.39 % 3.45 % 9.86 %
Seq. Cash & cash equivalent Change -93.24 % -73.48 % 217566.67 % 0 % -



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market # 0


Quick Ratio Statistics
High Average Low
0.51 0.05 0
(Jun 30 2019)   (Nov 30 2013)




Financial Statements
Regenerex Pharma's Current Liabilities $ 4 Millions Visit RGPX's Balance sheet
Regenerex Pharma's Cash & cash equivalent $ 0 Millions Visit RGPX's Balance sheet
Source of RGPX's Sales Visit RGPX's Sales by Geography


Cumulative Regenerex Pharma's Quick Ratio

RGPX's Quick Ratio for the trailling 12 Months

RGPX Quick Ratio

 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth 19.04 % 26.1 % 57.93 % 103.87 % 185.61 %
Y / Y Cash & cash equivalent TTM Growth 9646.51 % 5641.67 % 695.13 % -98.79 % -88.71 %
Quick Ratio TTM 0.05 0.05 0.04 0 0
Total Ranking TTM # 3265 # 3330 # 3436 # 4498 # 3965
Seq. Current Liabilities TTM Growth 1.25 % 3.56 % 6.02 % 7.08 % 7.25 %
Seq. Cash & cash equivalent TTM Growth 1.38 % 26.5 % 65260 % -88.37 % -40.28 %

Quick ratio ranking by company, industry and sector >> Back to RGPX Financial Strength Comparisons >> Go to Compare RGPX Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the decrease in Current Liabilities in the Q2 2025 to $3.87 millions, cumulative Quick Ratio remained unchanged at 0.05 above the RGPX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry RGPX achieved the highest Quick Ratio. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2025 from to 0.

Explain Quick Ratio?
How much Cash & cash equivalents RGPX´s has?
What are RGPX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Within the Market # 5340


trailing twelve months Quick Ratio Statistics
High Average Low
0.17 0.03 0
(Jun 30 2019)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Prophase Labs Inc   0.01 $ 0.405  Millions$ 55.287  Millions
Bioxytran Inc 0.00 $ 0.014  Millions$ 3.061  Millions
Accustem Sciences Inc 0.00 $ 0.014  Millions$ 4.484  Millions
REGENEREX PHARMA, INC. 0.00 $ 0.012  Millions$ 3.875  Millions
Celularity Inc 0.00 $ 0.120  Millions$ 65.314  Millions
Bioadaptives Inc 0.00 $ 0.003  Millions$ 1.590  Millions

Date modified: 2026-09-12T06:28:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.